Turning Point's TPX-0022 In Gastric Cancer Gets Orphan Drug Designation In US

by Vandana Singh, Benzinga Editor

June 17, 2021 10:20 AM | 30 seconds read | Make a Comment

The FDA has granted Orphan Drug Designation to Turning Point Therapeutics Inc's TPTX TPX-0022, for gastric cancer, including gastroesophageal junction adenocarcinoma.
TPX-0022 is a potent inhibitor of the MET tyrosine kinase, and currently, there are no approved MET inhibitors for gastric cancer.
Benefits of the designation may include the opportunity for accelerated approval, discounts on registration fees, tax credits for qualified clinical trials, and eligibility for seven years of market exclusivity post-regulatory approval.
Price Action: TPTX shares down 0.63% at $78.09 during the market session on the last check Thursday.

Posted In: Biotech News Health Care FDA General Biotechnology Briefs Health Care

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.